新华社快讯：分列式环节按空中护旗梯队、徒步方队、战旗方队、装备方队、空中梯队的顺序，依 次通过天安门广场。 ...

相关负责人介绍：分列式环节，按空中护旗梯队、徒步方队、战旗方队、装备方队、空中梯队的顺序， 依次通过天安门广场。 国务院新闻办公室今天上午举行新闻发布会，介绍阅兵准备工作有关情况，并答记者问。 （总台央视记者 黄惠馨 李峥） ...

【财华社讯】天安(00028.HK)公布，预期截至2025年6月30日止六个月，公司股东应占溢利介乎22亿至 24亿港元，较2024同期应占溢利约7800万港元显着上升。增长主要是由于位于中国上海住宅项目天安1 号二期(C区)单位于2025年初交付予客户后所确认收入，致毛利上升。 本文源自财华网 ...

Core Viewpoint - Tianan (00028.HK) expects a significant increase in profit attributable to shareholders, projecting between HKD 2.2 billion to HKD 2.4 billion for the six months ending June 30, 2025, compared to approximately HKD 78 million for the same period in 2024 [1] Summary by Relevant Sections - **Profit Forecast**: The company anticipates a profit attributable to shareholders ranging from HKD 2.2 billion to HKD 2.4 billion for the first half of 2025, marking a substantial increase from the previous year's profit of about HKD 78 million [1] - **Revenue Drivers**: The growth in profit is primarily attributed to the recognition of revenue from the delivery of units in the Tianan No. 1 Phase II (C District) residential project in Shanghai, China, expected to be delivered to customers in early 2025, leading to an increase in gross profit [1]

Core Viewpoint - Tianan Holdings (00028) has experienced a significant stock price increase of over 6% following the announcement of a positive earnings forecast for the first half of 2025, projecting a substantial rise in profit compared to the previous year [1] Financial Performance - The company anticipates a profit attributable to shareholders of approximately HKD 2.2 billion to HKD 2.4 billion for the first half of 2025, a notable increase from HKD 78 million in the same period of 2024 [1] - The expected profit growth is primarily driven by an increase in gross profit, attributed to revenue recognition from the delivery of residential units in the Tianan No. 1 Phase II (C District) project in Shanghai, scheduled for early 2025 [1]

Core Viewpoint - Tianan Holdings (00028) has experienced a significant stock price increase of over 6% following the announcement of a positive earnings forecast for the first half of 2025, projecting a substantial rise in profit attributable to shareholders [1] Financial Performance - The company anticipates a profit attributable to shareholders of approximately HKD 2.2 billion to HKD 2.4 billion for the first half of 2025, a notable increase from around HKD 78 million in the same period of 2024 [1] - The expected profit growth is primarily driven by an increase in gross profit, attributed to revenue recognition from the delivery of residential units in the Tianan No. 1 Phase II (C District) project in Shanghai, scheduled for early 2025 [1] Market Reaction - Following the earnings forecast announcement, Tianan's stock price rose by 6.69%, reaching HKD 5.1, with a trading volume of HKD 5.9393 million [1]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Group 1 - The company expects to achieve a profit attributable to shareholders of approximately HKD 2.2 billion to HKD 2.4 billion in the first half of 2025, a significant increase compared to HKD 78 million in the same period of 2024 [1] - The anticipated profit growth is primarily due to an increase in gross profit, mainly from the revenue recognized after the delivery of units in the Shanghai residential project, Tianan 1 Phase II (Zone C), to customers in early 2025 [1]

Core Viewpoint - The company anticipates a significant increase in profit attributable to shareholders, projecting a profit of approximately HKD 2.2 billion to HKD 2.4 billion in the first half of 2025, compared to HKD 78 million in the same period of 2024 [1] Group 1 - The expected profit growth is primarily driven by an increase in gross profit [1] - Revenue recognition is anticipated from the delivery of units in the Tianan No. 1 Phase II (C Zone) residential project in Shanghai, China, scheduled for early 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 正面盈利預告 本公佈乃天安中國投資有限公司(「本公司」，連同其附屬公司統稱「本集團」)根據香港聯合 交易所有限公司證券上市規則(「上市規則」)第 13.09(2)(a)條及香港法例第 571 章證券及期貨 條例第 XIVA 部項下之內幕消息條文（定義見上市規則)而作出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根據對本集團截 至二零二五年六月三十日止六個月之未經審核綜合管理賬目之初步評估，預期本公司股東應 佔溢利（「應佔溢利」）將介乎於 2,200 百萬港元至 2,400 百萬港元之間，較二零二四年六月三 十日止六個月之應佔溢利約 78 百萬港元顯著上升。有關預期應佔溢利增長主要是因為毛利上 升，主要由於位於中國上海住宅項目天安 1 號二期（C 區）單位於二零二五年初交付予客戶 後所確認之收入所致。 本公司仍正就本集團截至二零二五年六月三十日止六個月之中期業績作最後確定。本 ...